Literature DB >> 6387491

Leukocyte activation in allergen-induced late-phase asthmatic reactions.

S R Durham, M Carroll, G M Walsh, A B Kay.   

Abstract

Some patients with allergen-induced asthma have both an early and late reaction to allergen (dual asthmatic reactions). To investigate the role of leukocyte activation in dual asthmatic reactions, we measured neutrophil chemotactic activity, percentages of neutrophil and monocyte complement rosettes, and one-second forced expiratory volume (FEV1) in 11 patients with allergen-induced dual asthmatic reactions after a challenge with allergen. To control for the effects of bronchoconstriction, the same studies were done after a challenge with methacholine. In all subjects there was a biphasic increase in neutrophil chemotactic activity and the percentages of neutrophil and monocyte complement rosettes, accompanied by a reduction in the FEV1. After methacholine, there were no significant changes in neutrophil chemotactic activity or percentages of complement rosettes, despite bronchoconstriction. Six patients with single-phase allergen-induced asthma had similar responses, but they were monophasic. We conclude that allergen-induced early and late asthmatic reactions are accompanied by activation of leukocytes and that these alterations probably reflect the release of mediators from mast cells rather than an effect of bronchoconstriction.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6387491     DOI: 10.1056/NEJM198411293112202

Source DB:  PubMed          Journal:  N Engl J Med        ISSN: 0028-4793            Impact factor:   91.245


  18 in total

Review 1.  Leukocyte activation following IgE dependent mechanisms in bronchial asthma.

Authors:  S R Durham
Journal:  Clin Rev Allergy       Date:  1989

2.  Pharmacological modulation of the effects of N-formyl-L-methionyl-L-leucyl-L-phenylalanine in guinea-pigs: involvement of the arachidonic acid cascade.

Authors:  M A Boukili; M Bureau; V Lagente; J Lefort; A Lellouch-Tubiana; E Malanchère; B B Vargaftig
Journal:  Br J Pharmacol       Date:  1986-10       Impact factor: 8.739

3.  The inhibition of CR1 mobilization of human granulocytes by the presence of erythrocytes. A possible mechanism for intravascular regulation of granulocyte modulation.

Authors:  J Forslid; G Halldén; J Hed
Journal:  Immunology       Date:  1991-12       Impact factor: 7.397

4.  Diurnal variation in serum cortisol concentrations in asthmatic subjects after allergen inhalation.

Authors:  S R Durham; J Keenan; W O Cookson; C F Craddock; M K Benson
Journal:  Thorax       Date:  1989-07       Impact factor: 9.139

5.  Increased expression of CR3 (C3bi receptor) on neutrophils in human inflammatory skin reactions.

Authors:  M Shalit; C von Allmen; P C Atkins; B Zweiman
Journal:  J Clin Immunol       Date:  1987-11       Impact factor: 8.317

6.  Increase in numbers of CD8 positive lymphocytes and eosinophils in peripheral blood of subjects with late asthmatic reactions induced by toluene diisocyanate.

Authors:  S Finotto; L M Fabbri; V Rado; C E Mapp; P Maestrelli
Journal:  Br J Ind Med       Date:  1991-02

7.  A brief history of asthma and its mechanisms to modern concepts of disease pathogenesis.

Authors:  Stephen T Holgate
Journal:  Allergy Asthma Immunol Res       Date:  2010-05-06       Impact factor: 5.764

Review 8.  Nimesulide in the treatment of patients intolerant of aspirin and other NSAIDs.

Authors:  G E Senna; G Passalacqua; G Andri; A R Dama; M Albano; L Fregonese; L Andri
Journal:  Drug Saf       Date:  1996-02       Impact factor: 5.606

9.  Terpenes enhance metabolic activity and alter expression of adhesion molecules (Mac-1 and L-selectin) on human granulocytes.

Authors:  U Johard; A Eklund; J Hed; J Lundahl
Journal:  Inflammation       Date:  1993-08       Impact factor: 4.092

10.  Interference of anti-inflammatory and anti-asthmatic drugs with neutrophil-mediated platelet activation: singularity of azelastine.

Authors:  P Renesto; V Balloy; B B Vargaftig; M Chignard
Journal:  Br J Pharmacol       Date:  1991-06       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.